Results 11 to 20 of about 92,350 (272)

Tocilizumab for Treatment of Patients With Severe COVID–19: A Retrospective Cohort Study

open access: yesEClinicalMedicine, 2020
Background: Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 patients. Methods: In this retrospective cohort study, we analyzed hypoxic COVID–
Fahrettin Covut   +2 more
exaly   +3 more sources

Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis

open access: yesJournal of Ophthalmic Inflammation and Infection, 2023
Purpose The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available.
Mathilde Leclercq   +6 more
doaj   +2 more sources

Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome

open access: yesAnnals of Clinical and Translational Neurology
Objective This study aimed to assess the efficacy and safety of using tocilizumab in children with febrile infection‐related epilepsy syndrome (FIRES) and explore tocilizumab‐related changes in interleukin (IL)‐6 levels.
Yushan He   +7 more
doaj   +2 more sources

Early tocilizumab and outcomes in acute necrotizing encephalopathy

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Early tocilizumab and outcome in acute necrotising encephalopathy. Aim To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE). Method This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut‐
Velda X Han   +14 more
wiley   +2 more sources

Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis [version 1; peer review: 1 approved, 2 approved with reservations]

open access: yesF1000Research, 2021
Background: Several studies have revealed the potential use of tocilizumab in treating COVID-19 since no therapy has yet been approved for COVID-19 pneumonia.
Cahyo Wibisono Nugroho   +10 more
doaj   +1 more source

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study

open access: yesInternational Journal of Infectious Diseases, 2021
Objective: Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19 infections, and cytokine storm is associated with disease severity.
Edmund Huang   +5 more
doaj   +1 more source

LC-MS/MS method for the quantitation of serum tocilizumab in rheumatoid arthritis patients using rapid tryptic digestion without IgG purification

open access: yesJournal of Pharmaceutical Analysis, 2022
The quantitation of serum tocilizumab using liquid chromatography tandem-mass spectrometry (LC-MS/MS) method has not been widely applied in clinical settings because of its time-consuming and costly sample pretreatments.
Takashi Mochizuki   +6 more
doaj   +1 more source

Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report

open access: yesPediatric Rheumatology Online Journal, 2023
Background Tocilizumab is a humanized monoclonal antibody that acts as an IL-6 receptor antagonist. Intravenous tocilizumab is considered an option for children with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis.
Francesca Burlo   +7 more
doaj   +1 more source

Therapeutic effectiveness of tocilizumab in the treatment of cytokine release syndrome in patients with COVID-19 [PDF]

open access: yes, 2021
Introducción: tocilizumab, fue aprobado en el 2017 por la Food and Drugs Administration para el tratamiento del síndrome de liberación de citoquinas, por lo que se ha empleado en la terapéutica de pacientes graves por SARS-CoV 2.
Denis-Piedra, Daniel Alejandro   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy